对阿德福韦酯治疗慢性乙型肝炎患者血清HBV-DNA载量变化及不良反应的研究

发布时间：2018-03-21 19:35

  本文选题：阿德福韦酯　切入点：乙型肝炎　出处：《中国社区医师》2016年35期 　论文类型：期刊论文

【摘要】：目的:观察阿德福韦酯治疗慢性乙型肝炎患者的病毒载量变化及不良反应。方法:第一阶段(第0~24周)对照组予多烯磷胆碱酯胶囊,治疗组予阿德福韦酯;第二阶段(第25~48周)两组用药进行交换,于治疗24周、48周观察HBV-DNA变化。结果:24周时,治疗组和对照组HBV-DNA中位数较基线水平均有下降;48周时,对照组中位数较基线水平下降2.4 log10拷贝/m L,治疗组HBV-DNA中位数恢复到基线水平。药物可能相关的不良事件大多为轻中度,两组肾功能无明显变化。结论:阿德福韦酯常规剂量,能有效抑制病毒复制,具有良好的耐受性和安全性。
[Abstract]:Objective: to observe the changes of viral load and adverse reactions in patients with chronic hepatitis B treated with adefovir dipivoxil. In the second stage (25 ~ 48 weeks), the two groups were used to exchange drugs. The changes of HBV-DNA were observed at 24 weeks after treatment and 48 weeks after treatment. Results at the end of 24 weeks, the median HBV-DNA of the treatment group and the control group were decreased from the baseline level to 48 weeks. The median of control group was decreased by 2.4 log10 copy / mL compared with the baseline level, and the median of HBV-DNA returned to baseline level in the treatment group. Most of the possible adverse events related to drugs were mild to moderate, and there was no significant change in renal function between the two groups. Conclusion: the routine dose of adefovir ester, It can effectively inhibit virus replication and has good tolerance and safety.
【作者单位】： 商丘市第一人民医院;
【分类号】：R512.62
，

本文编号：1645246